GIST Support International - logo

GIST Support International - GIST In the News
GIST Imagery

Pfizer submits application to FDA for Sutent (SU11248)

Posted by Administrator (admin) on Mar 13 2006
GIST In the News >>
NEW YORK, August 10 -- Pfizer Inc said today that it has submitted a New Drug Application for its cancer medicine SU11248 (sunitinib malate), known as Sutent, to the U.S. Food and Drug Administration.

Pfizer is seeking FDA approval for Sutent as a treatment for malignant gastrointestinal stromal tumor and metastatic renal cell carcinoma among patients whose tumors do not respond to or do not tolerate standard treatment options.

The FDA has granted Sutent fast-track status since Sutent may provide significant benefit over existing therapy for serious or life-threatening illnesses for which no therapy exists.

Sutent is an oral, multi-targeted cancer therapy that combines anti-angiogenic and anti-tumor activity to simultaneously stop the blood supply to and directly attack tumor cells. Over 2,000 patients have received Sutent as part of Pfizer's clinical trial program.

Developed by Pfizer, Sutent also is being studied alone and in combination with other medicines as a treatment for a number of other solid tumors, including breast, lung, prostate, and colorectal cancers.

Sutent is one of the first in a new class of drugs that selectively targets multiple protein receptors, called receptor tyrosine kinases (RTKs). Inhibition of these RTKs is believed to starve tumors of blood and nutrients needed for growth and simultaneously kill the cancer cells that make up tumors.

Pfizer is committed to advancing the scientific understanding of cancer and to bringing new medicines that address unmet medical needs to cancer patients. Oncology is a research priority for Pfizer, with a significant portion of the company's research and development investment devoted to discovering and developing innovative therapies for treating breast, colorectal and other cancers.

Last changed: Mar 13 2006 at 10:17 AM

Back

back to top